Unknown

Dataset Information

0

Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study.


ABSTRACT:

Objective

To evaluate the effectiveness and safety of nab-paclitaxel plus platinum as first-line chemotherapy for ovarian cancer (OC).

Methods

Patients administered platinum combined with nab-paclitaxel as first-line chemotherapy for epithelial OC, fallopian tube cancer, or primary peritoneal cancer from July 2018 to December 2021 were retrospectively evaluated. The primary outcome was progression-free survival (PFS). Adverse events (AEs) were examined. Subgroup analysis was performed.

Results

Seventy-two patients (median age, 54.5 years; range, 20.0-79.0 years) were evaluated, including 12 and 60 administered neoadjuvant therapy and primary surgery with subsequent chemotherapy, respectively. The median follow-up duration was 25.6 months, and the median PFS was 26.7 (95% confidence interval [CI]=24.0-29.3) months in the whole patient population. In the neoadjuvant subgroup, the median PFS was 26.7 (95% CI=22.9-30.5) months vs. 30.1 (95% CI=23.1-37.1) months in the primary surgery subgroup. Twenty-seven patients were administered nab-paclitaxel plus carboplatin and had a median PFS of 30.3 (95% CI=not available [NA]-NA) months. The commonest grade 3-4 AEs included anemia (15.3%), white blood cell decreased (11.1%), and neutrophil count decreased (20.8%). No drug-related hypersensitivity reactions occurred.

Conclusion

Nab-paclitaxel plus platinum as first-line treatment in OC was associated with a favorable prognosis and was tolerable in patients with OC.

SUBMITTER: Wang L 

PROVIDER: S-EPMC10323297 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study.

Wang Liangliang L   Li Shuangying S   Zhu Da D   Qin Yu Y   Wang Xiaoli X   Hong Zhenya Z   Han Zhiqiang Z  

Journal of gynecologic oncology 20230206 4


<h4>Objective</h4>To evaluate the effectiveness and safety of nab-paclitaxel plus platinum as first-line chemotherapy for ovarian cancer (OC).<h4>Methods</h4>Patients administered platinum combined with nab-paclitaxel as first-line chemotherapy for epithelial OC, fallopian tube cancer, or primary peritoneal cancer from July 2018 to December 2021 were retrospectively evaluated. The primary outcome was progression-free survival (PFS). Adverse events (AEs) were examined. Subgroup analysis was perfo  ...[more]

Similar Datasets

| S-EPMC10501299 | biostudies-literature
| S-EPMC9178436 | biostudies-literature
| S-EPMC7364337 | biostudies-literature
| S-EPMC5448660 | biostudies-literature
| S-EPMC9346632 | biostudies-literature
| S-EPMC3631516 | biostudies-literature
| S-EPMC10774994 | biostudies-literature
| S-EPMC7283477 | biostudies-literature
| S-EPMC8306351 | biostudies-literature
| S-EPMC4674355 | biostudies-literature